Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03027128 · ClinicalTrials.gov registry record · Phase 1
QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
A Phase 1 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03027128 is a Phase 1 study that has completed, run by ImmunityBio. The registered enrollment target is 6 participants.
The verdict
NCT03027128, a Phase 1 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether haNK™ for Infusion is safe and effective in the treatment of metastatic or locally advanced solid tumors.
Interventions
- BIOLOGICAL haNK™ for Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03027128
The ClinicalTrials.gov registry entry for NCT03027128 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which haNK™ for Infusion is the first listed.
NCT03027128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03027128 about?
NCT03027128 is a clinical study titled "QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors". The purpose of this study is to determine whether haNK™ for Infusion is safe and effective in the treatment of metastatic or locally advanced solid tumors.
What is the current status of trial NCT03027128?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-08-02. Estimated completion is 2019-05-06.
What interventions are being tested in trial NCT03027128?
The interventions under investigation include: haNK™ for Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT03027128?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.